Thus, AAVHSC HR-based genome editing platform has tremendous potential for the precise and accurate correction of pathogenic MECP2 mutations associated with Rett syndrome in patient-derived cells with no evidence of on-target mutations or ITR insertions. The gene discussed is MECP2; the disease is Rett syndrome.